The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia Type 3 pathogenesis

DNA strand-breaks (SBs) with non-ligatable ends are generated by ionizing radiation, oxidative stress, various chemotherapeutic agents, and also as base excision repair (BER) intermediates. Several neurological diseases have already been identified as being due to a deficiency in DNA end-processing activities. Two common dirty ends, 3'-P and 5'-OH, are processed by mammalian polynucleotide kinase 3'-phosphatase (PNKP), a bifunctional enzyme with 3'-phosphatase and 5'-kinase activities. We have made the unexpected observation that PNKP stably associates with Ataxin-3 (ATXN3), a polyglutamine repeat-containing protein mutated in spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph Disease (MJD). This disease is one of the most common dominantly inherited ataxias worldwide; the defect in SCA3 is due to CAG repeat expansion (from the normal 14-41 to 55-82 repeats) in the ATXN3 coding region. However, how the expanded form gains its toxic function is still not clearly understood. Here we report that purified wild-type (WT) ATXN3 stimulates, and by contrast the mutant form specifically inhibits, PNKP's 3' phosphatase activity in vitro. ATXN3-deficient cells also show decreased PNKP activity. Furthermore, transgenic mice conditionally expressing the pathological form of human ATXN3 also showed decreased 3'-phosphatase activity of PNKP, mostly in the deep cerebellar nuclei, one of the most affected regions in MJD patients' brain. Finally, long amplicon quantitative PCR analysis of human MJD patients' brain samples showed a significant accumulation of DNA strand breaks. Our results thus indicate that the accumulation of DNA strand breaks due to functional deficiency of PNKP is etiologically linked to the pathogenesis of SCA3/MJD.

Protective effect of left ventricular hypertrophy in right coronary artery occlusions

OBJECTIVE: To test the hypothesis that left ventricular hypertrophy (LVH) reduces the electrocardiographic and functional effects of right coronary artery occlusion. METHODS: We analysed 215 patients (166 males and 49 women,age of 58.9±10.6 years), with occlusion of the right coronary artery without other associated lesions. There was no significant difference (p>0.05) in age and gender distribution between the 78 patients with LVH (left ventricular mass >100g/m²) (Group A) when compared with the 137 patients without LVH (left ventricular mass <100g/m²) (Group B). RESULTS: The electrocardiographic finding of transmural necrosis was more often found in group B patients than in group A patients (56.9% and 30.8%, respectively; p<0.05). The left ventricular function parameters of group A were better than those of group B: the ratio end-diastolic pressure/systolic pressure (EDP/SP) (A: 0.108±0.036; B: 0.121±0.050; p<0.05); the end-diastolic volume index (A: 75.9±31.3ml/m²; B: 88.0±31.0ml/m²; p<0.01); the end-systolic volume index (A: 16.0±10.0ml/m²; B: 27.0 ±20.0ml/m²; p<0.001); the ejection fraction (A 78.6±10.8%; B 67.7±17.9%; p<0.001); the anteroinferior shortening (A: 43.9±10.3%; B: 35.1±12.8%; p<0.001). A higher degree of coronary tortuosity was observed in group A than in group B (78.2% and 24.1%; p<0.001) and also a more frequent absent or minimal diaphragmatic hypokinetic area (A: 80.8%; B: 54.0%; p<0.05). CONCLUSION: LVH reduces the effects of myocardial sequela and protects LV function when right coronary occlusion develops.

Removal of ochratoxin A from contaminated white and red wines using oenological fining agents

Mycotoxins are toxic secondary metabolites produced by certain moulds, being ochratoxin A (OTA) one of the most relevant. Its chemical structure is a dihydro-isocoumarin connected at the 7-carboxy group to a molecule of L--phenylalanine via an amide bond. OTA contamination of wines might be a risk to consumer health, thus requiring treatments to achieve acceptable standards for human consumption [1]. According to the Regulation No. 1881/2006 of the European Commission, the maximum limit for OTA in wine is 2 µg/kg [2]. Therefore, the aim of this work was to know the effect of different fining agents on OTA removal, as well as their impact on white and red wine physicochemical characteristics. To evaluate their efficiency, 11 commercial fining agents (mineral, synthetic, animal and vegetable proteins) were used to get new approaches on OTA removal from white and red wines. Trials were performed in wines artificially supplemented (at a final concentration of 10 µg/L) with OTA. The most effective fining agent in removing OTA (80%) from white wine was a commercial formulation that contains gelatine, bentonite and activated carbon. Removals between 10-30% were obtained with potassium caseinate, yeast cell walls and pea protein. With bentonites, carboxymethylcellulose, polyvinylpolypyrrolidone and chitosan no considerable OTA removal was verified. In red wine, removals between 6-19% were obtained with egg albumin, yeast cell walls, pea protein, isinglass, gelatine, polyvinylpolypyrrolidone and chitosan. The most effective fining agents in removing OTA from red wine were an activated carbon (66%) followed again by the commercial formulation (55%), being activated carbon a well-known adsorbent of mycotoxins. These results may provide useful information for winemakers, namely for the selection of the most appropriate oenological product for OTA removal, reducing wine toxicity and simultaneously enhancing food safety and wine quality.

Food safety in wine: removal of ochratoxin A in contaminated white wine using commercial fining agents

The presence of mycotoxins in foodstuff is a matter of concern for food safety. Mycotoxins are toxic secondary metabolites produced by certain molds, being ochratoxin A (OTA) one of the most relevant. Wines can also be contaminated with these toxicants. Several authors have demonstrated the presence of mycotoxins in wine, especially ochratoxin A (OTA) [1]. Its chemical structure is a dihydro-isocoumarin connected at the 7-carboxy group to a molecule of L--phenylalanine via an amide bond. As these toxicants can never be completely removed from the food chain, many countries have defined levels in food in order to attend health concerns. OTA contamination of wines might be a risk to consumer health, thus requiring treatments to achieve acceptable standards for human consumption [2]. The maximum acceptable level of OTA in wines is 2.0 g/kg according to the Commission regulation No. 1881/2006 [3]. Therefore, the aim of this work was to reduce OTA to safer levels using different fining agents, as well as their impact on white wine physicochemical characteristics. To evaluate their efficiency, 11 commercial fining agents (mineral, synthetic, animal and vegetable proteins) were used to get new approaches on OTA removal from white wine. Trials (including a control without addition of a fining agent) were performed in white wine artificially supplemented with OTA (10 µg/L). OTA analysis were performed after wine fining. Wine was centrifuged at 4000 rpm for 10 min and 1 mL of the supernatant was collected and added of an equal volume of acetonitrile/methanol/acetic acid (78:20:2 v/v/v). Also, the solid fractions obtained after fining, were centrifuged (4000 rpm, 15 min), the resulting supernatant discarded, and the pellet extracted with 1 mL of the above solution and 1 mL of H2O. OTA analysis was performed by HPLC with fluorescence detection according to Abrunhosa and Venâncio [4]. The most effective fining agent in removing OTA (80%) from white wine was a commercial formulation that contains gelatine, bentonite and activated carbon. Removals between 10-30% were obtained with potassium caseinate, yeast cell walls and pea protein. With bentonites, carboxymethylcellulose, polyvinylpolypyrrolidone and chitosan no considerable OTA removal was verified. Following, the effectiveness of seven commercial activated carbons was also evaluated and compared with the commercial formulation that contains gelatine, bentonite and activated carbon. The different activated carbons were applied at the concentration recommended by the manufacturer in order to evaluate their efficiency in reducing OTA levels. Trial and OTA analysis were performed as explained previously. The results showed that in white wine all activated carbons except one reduced 100% of OTA. The commercial formulation that contains gelatine, bentonite and activated carbon (C8) reduced only 73% of OTA concentration. These results may provide useful information for winemakers, namely for the selection of the most appropriate oenological product for OTA removal, reducing wine toxicity and simultaneously enhancing food safety and wine quality.

Beta-adrenergic blocking agents in heart failure

Cardiac dysfunction in heart failure is widely recognized as a progressive process, regardless of the clinical signs and symptoms. An increase in cardiac sympathetic drive is one of the earliest neurohormonal responses occurring in patients with heart failure and may be one of the major causes of the progressive remodeling leading to the decline in myocardial function, and responsible for the poor prognosis of patients with heart failure. Therefore, recent data provided by several appropriately designed clinical trials clearly indicate the benefits of beta-adrenoceptor blocking agents, combined with diuretics, ACE inhibitors, and digoxin in chronic heart failure class II to IV due to systolic ventricular dysfunction. The benefits are related to symptoms, functional capacity, remodeling, and improvement in left ventricular function, reduction in cardiovascular hospitalization, a decrease in the overall and sudden cardiac death rate, and are similar in patients with ischemic or nonischemic cardiomyopathy, independent of age, gender, or functional class. In this review we describe the cardiovascular effects of the increase in sympathetic drive, the pharmacological properties of the beta-blockers most evaluated in heart failure therapy (metoprolol, bisoprolol, and carvedilol), the major clinical trials related to these agents in heart failure, the recommendations for their appropriate use in clinical practice, the precautions to be adopted, and how to handle the more common adverse reactions.

Alcohol and atherosclerosis

Observational studies have attributed a protective effect to alcohol consumption on the development of atherosclerosis and cardiovascular morbidity and mortality. Alcohol intake in the amount of one to two drinks per day results in an estimated 20-40% reduction in cardiovascular events. An additional protective effect, according to major cohort studies, has been attributed to wine, probably due to antioxidant effects and platelet antiaggregation agents. On the other hand, the influence of different patterns of alcohol consumption and environmental factors may explain a great part of the additional effect of wine. Protection may be mediated by modulation of other risk factors, because alcohol increases HDL-C, produces a biphasic response on blood pressure, and modulates the endothelial function, while it neither increases body weight nor impairs glucose-insulin homeostasis. Alcohol may also have a direct effect on atherogenesis. Despite these favorable effects, the current evidence is not enough to justify prescribing alcohol to prevent cardiovascular disease.

Agentes deletéreos para Trypanosoma cruzi: Patogenia de la infección de placenta humana en la enfermedad congénita de Chagas, in vitro. Deleterious agents to Trypanosoma cruzi: Pathogenia of the human placenta infection in the congenital Chagas disease.

Trypanosoma cruzi, agente causal del Chagas, atraviesa la barrera placentaria y produce la enfermedad congénita. Objetivo general: Analizar si el T. cruzi, agente causal del Chagas, produce alteraciones trofoblásticas de las vellosidades coriónicas mediadas por óxido nítrico (principal agente deletéreo contra T. cruzi) y estrés oxidativo con variaciones que pudieran depender de la disponibiidad de L-arginine, sobre placentas en modelos in vitro de co-cultivos de explantos de vellosidades coriónicas, de sinciciotrofoblasto aislado y de células derivadas del trofoblasto de placentas humanas en interacción con distintas cepas del Trypanosoma cruzi, que pudieran dar alguna luz en la explicación de mecanismos involucrados en la infección placentaria y en algunos síndromes clínicos de la transmisión congénita del Chagas. Objetivos Específicos: a) Describir alteraciones estructurales y presencia de T. cruzi en vellosidades coriónicas de placentas humanas procedentes de co-cultivos con Trypanosoma cruzi in vitro (y sus respectivos controles), mediante técnicas histológicas y PCR analizando secuencias de ADN específicas del parásito.b) Establecer la localización y expresión proteica y la expresión transcripcional de las isoformas II y III de la Öxido Nítrico Sintasa sobre la misma población muestral de (a) mediante técnicas inmunohistoquímica, RT-PCR y semicuantificación con software adecuado. c) Analizar la susceptibilidad a la infección por el T. cruzi del citotrofoblasto (CTB) y sinciciotrofoblasto (STB) placentario aislado in vitro. d) Determinar concentraciones de óxido nítrico y estrés oxidativo del sinciciotrofoblasto (STB) aislado ante la infección por T. cruzi. e) Relacionar concentraciones de L-arginina con infección del trofoblasto aislado. f) Relacionar inhibiciones de la eNOS y de la arginasa con infección trofoblástica y óxido nítrico producido.Se emplearán métodos y técnicas de Biología celular y molecular, mediciones hormonales, enzimáticas, proteicas, parasitarias y bioquímicas en medios sobrenadantes de cultivo, de inmuno-detección de epitopes proteicos en tejidos, expresión de ARN por RT-PCR, Western blot, detección de DNA en tejidos por PCR, Cuantificaciones morfométricas. En general, el presente proyecto podría redundar en beneficios para un sector de la población de las áreas endémicas para esta enfermedad de bajos recursos económicos, sociales y culturales, mediante la obtención de datos que pudieran explicar algunos mecanismos de síndromes clínicos descriptos en esta patología y que pudieran participar en la transmisión congénita de la enfermedad de Chagas.

Estudios in vitro e in vivo de agentes fotosensibilizadores y su aplicación en terapia fotodinámica. In vitro and in vivo studies of photosensitizer agents and its application in photodynamic therapy.

Muchos esfuerzos se están realizando en el diseño de nuevos métodos para la eliminación de las células tumorales y así inhibir el crecimiento neoplásico. Entre los métodos no convencionales se encuentran la Terapia Fotodinámica.La Terapia Fotodinámica (TFD) es un tratamiento experimental de algunos tipos de cáncer, basado en el efecto citotóxico inducido en el tejido tumoral, por la acción combinada de una droga (fotosensibilizador) y la luz visible. El fotosensibilizador posee la propiedad de absorber la luz y reaccionar con el oxígeno molecular, produciendo una forma activa del oxígeno: el oxígeno singlete (1O2) que oxida diversas moléculas biológicas, induciendo un efecto citotóxico que se traduce en la regresión tumoral. Los nuevos avances en la dosimetría de la luz, así como la búsqueda de una segunda generación de nuevos fotosensibilizadores más eficaces que los actualmente utilizados, han permitido incluir protocolos de Terapia Fotodinámica en numerosos centros hospitalarios principalmente para el tratamiento de cánceres de pulmón, vejiga, esófago y piel. Plantas fototóxicas, sus metabolitos fotosensibilizantes y sus posibles usos; En general, dentro de las especies vegetales tóxicas existen aquellas denominadas plantas alergénicas, que son las que pueden producir sus efectos indeseables por vía dérmica. También existen aquellas que pueden producir efectos tóxicos por vía sistémica. Sin embargo, coexiste en la naturaleza otro grupo de plantas tóxicas que desencadenan sus efectos nocivos bajo la acción de la luz, por lo que son llamadas plantas fototóxicas, cuyos principios activos son comúnmente denominados agentes fotosensibilizantes La apoptosis como blanco terapéutico contra el cáncer: Los conocimientos moleculares sobre la apoptosis adquiridos en los últimos años están siendo aplicados al desarrollo de nuevos fármacos que puedan modular selectivamente las señales involucradas en la muerte de las células. Una de las razones que justifica el interés en el estudio de este tipo de moléculas, es que una de las características más tempranas en la transformación de la células neoplásicas esta relacionada con la incapacidad de responder a los estímulos de muerte. Esto lleva a una desregulación del proceso de apoptosis desencadenando una proliferación descontrolada. Los otros eventos que desencadenan el cáncer son, la invasión vascular y la metástasis a distanciaLa adquisición de resistencia a los efectos citotóxicos de los tratamientos anticancerígenos ha emergido como un significante impedimento para el efectivo tratamiento de la enfermedad. Por ello, en el presente proyecto se investigará si la adquisición de resistencia a TFD inducida en la línea celular estudiada es conferida por el aumento de la proteína MDRP1 a través de la vía de señalización PI3K/Akt. Además, se estudiará la correlación entre la posible resistencia a drogas y la inducción de apoptosis, analizando los mecanismos involucrados. Los resultados obtenidos contribuirán a dilucidar y entender los mecanismos moleculares implicados en la resistencia y sensibilidad tumoral a la TFD, y de esta manera mejorar la eficacia de dicha terapia antitumoral para sensibilizar a las células a la apoptosis. OBJETIVOS Estudiar el efecto de agentes fotosensibilizadores de origen sintético (ftalocianinas), comercialmente ya aprobadas por la FDA (Me-ALA), de origen natural (antraquinonas), y obtenidas en procesos nanotecnologicos (nanofibras) respecto a su capacidad de inducir la muerte celular en sistemas experimentales in vivo, para el desarrollo de nuevas drogas de aplicación en Terapia Fotodinámica (PDT). Estudiar las señales de apoptosis que se desencadenan, combinando la PDT con iRNA (antisurvivina) con la finalidad de aumentar la eficiencia de la muerte tumoral. Estudiar los mecanismos de resistencia a la Terapia Fotodinámica en carcinoma de células escamosas con fotosensibilizadores permitidos (Me-ALA).

Search for very high energy Gamma radiation from the Starburst Galaxy IC 342

This thesis describes a search for very high energy (VHE) gamma-ray emission from the starburst galaxy IC 342. The analysis was based on data from the 2003 — 2004 observing season recorded using the Whipple 10-metre imaging atmospheric Cherenkov telescope located on Mount Hopkins in southern Arizona. IC 342 may be classed as a non-blazar type galaxy and to date only a few such galaxies (M 87, Cen A, M 82 and NGC 253) have been detected as VHE gamma-ray sources. Analysis of approximately 24 hours of good quality IC 342 data, consisting entirely of ON/OFF observations, was carried out using a number of methods (standard Supercuts, optimised Supercuts, scaled optimised Supercuts and the multivariate kernel analysis technique). No evidence for TeV gamma-ray emission from IC 342 was found. The significance was 0.6 a with a nominal rate of 0.04 ± 0.06 gamma rays per minute. The flux upper limit above 600 GeV (at 99.9 % confidence) was determined to be 5.5 x 10-8 m-2 s-1, corresponding to 8 % of the Crab Nebula flux in the same energy range.

Some results of study of variations of light ions concentration and their connections with the ionizing radiation and sub-micron aerosol content in air under the conditions of Tbilisi city

Results of analysis of variations of sum light ions concentration and their connections with radon, galactic cosmic rays intensity and content of sub-micron aerosols by diameter ≥ 0.1 micron in surface boundary layer of Tbilisi city are given.

The Feedback Effect of Intensity of Ionizing Radiation With the Light Ions Content in Atmosphere. Paradox (the Tbilisi Type of a Smog), or Usual Phenomenon for the Strongly Pollution Cities?.

თბილისში მსუბუქი იონების, რადონის და გალაქტიკური კოსმოსური სხივების ნეიტრონული კომპონენტის ინტენსივობის 2009-2010 წლებში კომპლექსური მონიტორინგის მონაცემების მიხედვით გამოვლენილია მაიონიზებელი გამოსხივების ინტენსივობისა და ატმოსფეროში მსუბუქი იონების შემცველობის უკუკავშირის ეფექტი.

A Comparison of Radiation Dose Between Standard and 3D Angiography in Congenital Heart Disease

Background: The use of three-dimensional rotational angiography (3D-RA) to assess patients with congenital heart diseases appears to be a promising technique despite the scarce literature available. Objectives: The objective of this study was to describe our initial experience with 3D-RA and to compare its radiation dose to that of standard two-dimensional angiography (2D-SA). Methods: Between September 2011 and April 2012, 18 patients underwent simultaneous 3D-RA and 2D-SA during diagnostic cardiac catheterization. Radiation dose was assessed using the dose-area-product (DAP). Results: The median patient age and weight were 12.5 years and 47.5 Kg, respectively. The median DAP of each 3D-RA acquisition was 1093µGy.m2 and 190µGy.m2 for each 2D-SA acquisition (p<0.01). In patients weighing more than 45Kg (n=7), this difference was attenuated but still significant (1525 µGy.m2 vs.413µGy.m2, p=0.01). No difference was found between one 3D-RA and three 2D-SA (1525µGy.m2 vs.1238 µGy.m2, p = 0.575) in this population. This difference was significantly higher in patients weighing less than 45Kg (n=9) (713µGy.m2 vs.81µGy.m2, P = 0.008), even when comparing one 3D-RA with three 2D-SA (242µGy.m2, respectively, p<0.008). 3D-RA was extremely useful for the assessment of conduits of univentricular hearts, tortuous branches of the pulmonary artery, and aorta relative to 2D-SA acquisitions. Conclusions: The radiation dose of 3D-RA used in our institution was higher than those previously reported in the literature and this difference was more evident in children. This type of assessment is of paramount importance when starting to perform 3D-RA.

Protease-activated receptor (PAR)-1 and PAR-2 protect rat astrocytes from apoptotic cell death via differentially regulating JNK isoform-specific release of the chemokine GRO/CINC-1 : two novel protective pathways in brain

Protease-activated receptor; c-Jun N-terminal kinase (JNK); thrombin; neuroprotection; siRNA

Co-administration of Apelin and T4 Protects Inotropic and Chronotropic Changes Occurring in Hypothyroid Rats

AbstractBackground:One of the most important thyroid hormone targets is the cardiovascular system. Hemodynamic changes, such as decreased resting heart rate (HR), myocardial contractility, and cardiac output, and increased diastolic pressure and systemic vascular resistance, have been observed in hypothyroid patients. Moreover, in these patients, ECG changes include sinus bradycardia and low voltage complexes (P waves or QRS complexes).Objective:This study aimed at evaluating the prophylactic effect of apelin on HR changes and QRS voltage that occur in propylthiouracil (PTU)-induced hypothyroid rats.Method:In this study, 48 adult male Wistar rats weighing 170-235g were randomly divided into 6 groups: Control group (normal saline ip injection + tap water gavage); P group (PTU 0.05%, in drinking water); A group (apelin 200 µg.kg-1.day-1, ip); PA group [co-administration of PTU and apelin]; PT group [co-administration of PTU + T4 (0.2 mg/g per day, gavage)]; and PAT group (co-administration of PTU, apelin and T4). All experiments were performed for 28 consecutive days, and then the animals were anesthetized with an ip injection of ketamine (80 mg/kg) and xylazine (12 mg/kg). Lead II electrocardiogram was recorded to calculate HR and QRS voltage.Results:Heart rate and QRS voltage increased more significantly in the hypothyroid group that consumed both apelin and T4 (201 ± 4 beat/min, 0.71 ± 0.02 mv vs. hypothyroid 145 ± 9 beat/min, 0.563 ± 0.015 mv; respectively).Conclusion:The co-administration of apelin and T4 showed a protective effect on QRS voltage and HR in PTU‑induced hypothyroid rats.